(Q33619309)

28 July 2017

title

Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. (English)

1 reference

28 July 2017

15

Anton Simeonov

1 reference

28 July 2017

Mindy I Davis

1

1 reference

28 July 2017

Stefan Gross

2

1 reference

28 July 2017

Min Shen

3

1 reference

28 July 2017

Kimberly S Straley

4

1 reference

28 July 2017

Rajan Pragani

5

1 reference

28 July 2017

Wendy A Lea

6

1 reference

28 July 2017

Janeta Popovici-Muller

7

1 reference

28 July 2017

Byron DeLaBarre

8

1 reference

28 July 2017

Erin Artin

9

1 reference

28 July 2017

Natasha Thorne

10

1 reference

28 July 2017

Douglas S Auld

11

1 reference

28 July 2017

Zhuyin Li

12

1 reference

28 July 2017

Lenny Dang

13

1 reference

28 July 2017

Matthew B Boxer

14

1 reference

28 July 2017

language of work or name

English

0 references

publication date

25 March 2014

1 reference

28 July 2017

number of pages

9

1 reference

Journal of Biological Chemistry

inferred from page(s)

published in

1 reference

28 July 2017

volume

289

1 reference

28 July 2017

issue

20

1 reference

28 July 2017

page(s)

13717-13725

1 reference

Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022846

An R132H mutation in isocitrate dehydrogenase 1 enhances p21 expression and inhibits phosphorylation of retinoblastoma protein in glioma cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022846

Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022846

Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022846

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022846

(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022846

Evolution of the cancer genome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022846

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022846

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022846

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022846

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022846

Cancer genome sequencing: a review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022846

Advances in the integration of drug metabolism into the lead optimization paradigm

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022846

Metabolic enzymes as oncogenes or tumor suppressors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022846

IDH1 and IDH2 mutations in gliomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022846

An integrated genomic analysis of human glioblastoma multiforme

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022846

Glioblastoma cells release factors that disrupt blood-brain barrier features

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4022846

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1074%2FJBC.M113.511030

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1074%2FJBC.M113.511030

High throughput microsomal stability assay for insoluble compounds

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24668804

12 December 2020

inferred from PubMed ID database lookup

A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of αHG

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24668804

12 December 2020

inferred from PubMed ID database lookup

Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24668804

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1074/JBC.M113.511030

1 reference

28 July 2017

1 reference

28 July 2017

1 reference